Rodman & Renshaw Techvest Global Healthcare Conference 2005 Exhibitor Profiles.

PARIS -- The Rodman & Renshaw Techvest Global Healthcare Conference takes place at the Intercontinental Hotel in Paris, from 4th May to 6th May 2005. For in-depth information about the event visit http://www.rodmanandrenshaw.com .

Below are profiles from Rodman & Renshaw Techvest Global Healthcare Conference exhibitors; breaking news releases are available at http://www.tradeshownews.com, Business Wire's trade show, conference and event news resource. Business Wire is the official news wire service for the Rodman & Renshaw Techvest Global Healthcare Conference.

Company: Active Biotech AB
Ticker Symbol & Exchange: ACTI.SE  SEK
Investor Relations Contact: Cecilia Hofvander
Investor Relations Contact Phone: [phone]
Web: www.activebiotech.com
Date of Presentation: May 4

Company description: Active Biotech AB is a biotechnology company
focusing on research and development of pharmaceuticals. Active
Biotech has a strong R&D portfolio with pipeline products focused on
autoimmune/inflammatory diseases and cancer. Most advanced projects
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis,
as well as ANYARA for use in cancer immunotherapy with the primary
indication non-small cell lung cancer. Further key projects in
clinical development comprise the three orally administered compounds
TASQ for prostate cancer 57-57 for SLE and RhuDex(R) for RA.

Company: Advancis Pharmaceutical Corp.
Ticker Symbol & Exchange: AVNC (NASDAQ)
Investor Relations Contact: Bob Bannon
Investor Relations Contact Phone: [phone]
Web: www.advancispharm.com
Date of Presentation: 05-04-05

Company description: Advancis is a pharmaceutical company focused
on developing and commercializing pulsatile drug products that fulfill
unmet medical needs in the treatment of infectious disease. Based on
the Company's finding that bacteria exposed to antibiotics in
sequential bursts, or pulses, are killed more efficiently than those
exposed to standard treatment regimens, Advancis has developed a
proprietary, once-a-day pulsatile delivery technology for antibiotics
and other anti-infectives called PULSYS(TM). The Company currently has
two pulsatile amoxicillin drug candidates in Phase III clinical
trials, four pulsatile drugs or drug combinations in preclinical
development and is exploring pulsatile formulations for a range of
other antibiotics.

Company: ADVENTRX Pharmaceuticals
Ticker Symbol & Exchange: ANX (AMEX)
Investor Relations Contact: Ioana Nicodin
Investor Relations Contact Phone: [phone]
Web: www.adventrx.com
Date of Presentation: Thursday, May 5

Company description: ADVENTRX Pharmaceuticals is a
biopharmaceutical research and development company focused on
introducing new technologies for anticancer and antiviral treatments
that improve the performance of existing drugs and address significant
problems such as drug metabolism, bioavailability and resistance. The
Company holds exclusive rights to two new cancer drugs and four new
agents for HIV/AIDS therapy. The Company's lead compound, CoFactor, is
designed to improve the performance of the widely used
chemotherapeutic, 5-fluorouracil.

Company: Anika Therapeutics
Ticker Symbol & Exchange: ANIK (NASDAQ)
Investor Relations Contact: Rob Whetstone
Investor Relations Contact Phone: [phone]
Web: www.anikatherapeutics.com
Date of Presentation: May 5, 2005

Company description: Anika develops, manufactures and
commercializes therapeutic products and devices intended to promote
the repair, protection and healing of bone, cartilage and soft tissue.
These products are based on hyaluronic acid (HA), a naturally
occurring, biocompatible polymer found throughout the body. Anika
products include OrthoVisc(R), a treatment for osteoarthritis of the
knee available internationally and marketed in the U.S. by Ortho
Biotech Products, L.P., and Hyvisc(R), a treatment for equine
osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica,
Inc. Anika manufactures Amvisc(TM) and Amvisc Plus(TM), HA
viscoelastic products for ophthalmic surgery. It also produces
CoEase(TM), which is marketed by Advanced Medical Optics, Inc.,
STAARVISC(TM)-II distributed by STAAR Surgical Company and
Shellgel(TM) for Cytosol Ophthalmics, Inc.

Company: Avanir Pharmaceuticals
Ticker Symbol & Exchange: AVN (AMEX)
Investor Relations Contact: Patrice Saxon
Investor Relations Contact Phone: [phone]
Web: www.avanir.com / www.pseudobulbar.com
Date of Presentation: May 4, 2005 at 10:50 a.m.

Company description: Avanir Pharmaceuticals is a drug discovery
and development company that is rapidly approaching a major inflection
point. Our lead product candidate Neurodex(TM), is the subject of a
"rolling" NDA for the treatment of pseudobulbar affect, a neurological
disorder that affects one million people in the U.S. Avanir expects to
submit the final module to the U.S. FDA in mid-year 2005. Our product
candidates address therapeutic markets that include central nervous
system and cardiovascular disorders, inflammation, and infectious
disease. The Company's first commercialized product, Abreva(R), is
marketed in North America by GlaxoSmithKline Consumer Healthcare and
is the leading over-the-counter product for the treatment of cold
sores.

Company: AVI BioPharma
Ticker Symbol & Exchange: AVII (NASDAQ)
Investor Relations Contact: Michael Hubbard
Investor Relations Contact Phone: [phone]
Web: www.avibio.com
Date of Presentation: May 5, 2005

Company description: AVI BioPharma develops therapeutic products
for the treatment of life-threatening diseases using third-generation
NEUGENE(R) antisense drugs. AVI's lead NEUGENE antisense compound is
designed to target cell proliferation disorders, including
cardiovascular restenosis, cancer and polycystic kidney disease. In
addition to targeting specific genes in the body, AVI's antiviral
program uses NEUGENE antisense compounds to combat disease by
targeting single-stranded RNA viruses, including West Nile virus,
hepatitis C virus, dengue virus and Ebola virus. More information
about AVI is available on the company's Web site at
http://www.avibio.com.

Company: AXONXYX INC.
Ticker Symbol & Exchange: AXYX
Investor Relations Contact: Dawn Lauer
Investor Relations Contact Phone: [phone]
Web: www.axonyx.com
Date of Presentation: May 4, 2005

Company description: Axonyx Inc. is a biopharmaceutical company
engaged in the acquisition and development of proprietary
pharmaceutical compounds and new technologies for the treatment of
Alzheimer's Disease and other Central Nervous System disorders (CNS).
Axonyx' business strategy is rooted in four core areas: 1) Focused
Pipeline of proprietary compounds that fulfill unmet medical needs, 2)
Aggressive Growth Strategy that seeks to leverage in- and
out-licensing opportunities, 3) Responsive Operational Network of
dedicated high performance and experienced service providers and 4)
Financial Strength allowing robust product development and pipeline
growth.

Axonyx has acquired worldwide exclusive patent rights to three
main classes of therapeutic compounds designed for the treatment of
Alzheimer's disease (AD) and other CNS disorders.

Company: BioSante Pharmaceuticals, Inc.
Ticker Symbol & Exchange: BPA (AMEX)
Investor Relations Contact: Phillip Donenberg
Investor Relations Contact Phone: [phone] ext. 101
Web: www.biosantepharma.com
Date of Presentation: May 5, 2005

Company description: BioSante is developing a pipeline of hormone
therapy products to treat both men and women. These hormone therapy
products are gel formulations for transdermal administration that
deliver bioidentical estradiol and testosterone. BioSante's lead
products include Bio-E-Gel(TM) (bioidentical estradiol gel) for the
treatment of women with menopausal symptoms, and LibiGel(TM)
(bioidentical testosterone gel) for the treatment of female sexual
dysfunction (FSD). The current market in the U.S. for estrogen and
testosterone products is approximately $2.5 billion. The company also
is developing its calcium phosphate nanotechnology (CAP) for novel
vaccines, including biodefense vaccines for toxins such as anthrax and
ricin, and drug delivery systems. Additional information is available
online at www.biosantepharma.com.

Company: Biotica Technology Limited
Investor Relations Contact: Michael Hayes
Investor Relations Contact Phone: [phone]
Web: www.biotica.com
Date of Presentation: May 4, 2005

Company description: Biotica is using manipulation of polyketide
biosynthetic pathways for drug discovery. This is a powerful approach
to getting at the modification of natural products, which are not
amenable to normal organic synthesis. This allows Biotica to use a
spectrum of known compounds, including some high value marketed
products, to make focused libraries of proprietary derivatives with
altered bioactivity and pharmacokinetic profiles. This is an
attractive way of managing discovery risk: working with targets, and
in chemical space, that is already quite well validated, and where
Biotica is able to make compounds that are largely inaccessible to
others, but look like promising drugs. Biotica's main focus is in
oncology, working on three oncology targets: mTOR, HSP90 and
angiogenesis inhibition.

Company: BioVex Limited
Investor Relations Contact: Dr. Gareth Beynon
Investor Relations Contact Phone: [phone]
Web: www.biovex.com
Date of Presentation: Not yet known

Company description: BioVex is a clinical stage six year old
private biotech company developing prophylactic and therapeutic
vaccines for cancer and chronic infectious diseases. The Company has
two unique/proprietary product platforms -- OncoVEX and ImmunoVEX,
based on the manipulation of the herpes simplex virus. OncoVEX, a
unique oncolytic vaccine, has completed a Phase I clinical trial and
will enter multiple Phase II trials later in 2005. ImmunoVEX is in a
Phase I/II trial in malignant melanoma. The Company is headquartered
near Oxford, UK, with an office in Cambridge, Mass.

Company: CepTor Corporation
Ticker Symbol & Exchange: CEPO
Investor Relations Contact: Donald W. Fallon
Investor Relations Contact Phone: [phone] x22
Web: www.ceptorcorp.com
Date of Presentation: May 4, 2005

Company description: CepTor Corporation is a biopharmaceutical
company focusing on the development of cell targeted therapeutic
products for neuromuscular and neurodegenerative diseases. The
Company's mission is to increase the quality and quantity of life of
the people who suffer from these diseases. CepTor is preparing to file
an investigational new drug application (IND) and move its lead
product, MYODUR, into phase I/II clinical trials for Duchenne's
muscular dystrophy. The Company is also developing potential products
for multiple sclerosis and epilepsy. CepTor's platform technology is
expected to produce several low-risk, orphan drug candidates for
internal development and non-orphan product opportunities for
corporate partnering.

Company: ChemGenex Pharmaceuticals Limited
Ticker Symbol & Exchange: CXS (ASX)
Investor Relations Contact: Greg Collier
Investor Relations Contact Phone: [phone]
Web: www.chemgenex.com
Date of Presentation: May 4, 2005

Company description: Our mission at ChemGenex is to develop
targeted medicines for the treatment of cancer, diabetes, obesity and
depression. By focusing on validated targets in diseases with genetic
components, we seek to bring targeted therapeutics to market that
address chronic diseases with high unmet medical need. Our clinical
pipeline of cancer drugs, coupled with our partnered discovery and
development programs in diabetes and depression, provide us with a
solid foundation to meet these objectives.

Company: Crucell N.V.
Ticker Symbol & Exchange: CRXL
Investor Relations Contact: L. Kruimer, CFO F. van Egmond
Investor Relations Contact Phone: [phone]
Web: www.crucell.com
Date of Presentation: May 4, 2005

Company description: Crucell N.V. is a biotechnology company
focused on developing vaccines and antibodies that prevent and treat
infectious diseases, including Ebola, influenza, malaria, West Nile
virus and rabies. Crucell's products are based on its innovative
PER.C6(R) technology, which offers a safer, more efficient way to
produce biopharmaceuticals. The company licenses its PER.C6(R)
technology to the biopharmaceutical industry on a mostly non-exclusive
basis. Licensees and partners include DSM Biologics, GSK, Centocor/J&J
and Merck & Co., Inc. Crucell is headquartered in Leiden, The
Netherlands, and is listed on the NASDAQ and Euronext stock exchanges
(ticker symbol CRXL).

Company: CytRx Corporation
Ticker Symbol & Exchange: CYTR (NASDAQ)
Investor Relations Contact: Ed Umali, Jody Cain
Investor Relations Contact Phone: [phone] ext. 309, 310-691-7100
Web: www.cytrx.com
Date of Presentation: May 4, 2005, 10:10 a.m.

Company description: CytRx is a world leader in the development of
high-value therapeutics utilizing its core technologies in small
molecule drugs, RNAi drug discovery and DNA vaccines. The company's
small molecule therapeutics program involves R&D of oral drug
candidates, the first of which, arimoclomol, is expected to enter
Phase II clinical trials for ALS (Lou Gehrig's disease) during the 2nd
quarter of 2005. Two further Phase II clinical trials are possible in
2006 based on its small molecule drug candidates. CytRx, in
collaboration with University of Massachusetts Medical School and
Advanced Bioscience Laboratories and funded by a $16 mill grant from
the NIAID, is developing a DNA-based HIV vaccine currently in Phase I
clinical trials. CytRx is also conducting RNAi-based drug discovery
research to identify new approaches to treat metabolic diseases.

Company: Diversa Corporation
Ticker Symbol & Exchange: DVSA (NASDAQ)
Investor Relations Contact: Martin Sabarsky
Investor Relations Contact Phone: [phone]
Web: www.diversa.com
Date of Presentation: May 5, 2005

Company description: Diversa Corporation is a leader in applying
proprietary genomic technologies for the rapid discovery and
optimization of novel protein-based products. The Company is directing
its integrated portfolio of technologies to the discovery, evolution,
and production of commercially valuable molecules with agricultural,
chemical, industrial, and pharmaceutical applications. Diversa has
established alliances and joint ventures with market leaders, such as
Bayer Animal Health, DuPont, Cargill, GlaxoSmithKline, Medarex, Merck,
and Xoma. In addition, the Company has formed a broad strategic
relationship with Syngenta AG, a world-leading agribusiness company.
Diversa has commercialized products both independently and in
collaboration with strategic partners and licensees.

Company: EntreMed, Inc.
Ticker Symbol & Exchange: ENMD
Investor Relations Contact: Ginny Dunn
Investor Relations Contact Phone: [phone]
Web: www.entremed.com
Date of Presentation: Wednesday, May 4, 2005

Company description: EntreMed is a clinical-stage pharmaceutical
company focused on developing the next generation of multi-mechanism
oncology and anti-inflammatory drugs which directly target disease
cells and the blood vessels that nourish them, are safe and
convenient, and provide the potential for improved patient outcomes.
Panzem(R) (2-methoxyestradiol or 2ME2), the Company's lead drug
candidate, is currently in clinical trials for cancer, as well as in
preclinical development for non-oncology indications.

Company: Evotec OAI AG
Ticker Symbol & Exchange: EVT (FWB)
Investor Relations Contact: Anne Hennecke
Investor Relations Contact Phone: [phone]
Web: www.evotecoai.com
Date of Presentation: 4 May 2005, 11.15 a.m.

Company description: Evotec OAI is a leader in the discovery and
development of the next generation of novel small molecule drugs. In
its own discovery programmes, the Company specialises in finding new
treatments for diseases of the central nervous system, which were
expanded in March 2005 through the acquisition of Evotec
Neurosciences. The Company now has a number of products in late stage
pre-clinical development, the most advanced of which, a subtype
selective NMDA receptor antagonist for the treatment of Alzheimer's
disease, Parkinson's disease and neuropathic pain, is expected to
enter clinical trials later this year. In contract research, Evotec
OAI provides innovative solutions from drug target to clinic through
an unmatched range of integrated capabilities, including assay
development/screening through to medicinal chemistry and drug
manufacturing.

Company: Favrille, Inc.
Ticker Symbol & Exchange: FVRL (NASDAQ)
Investor Relations Contact: Tamara A. Seymour
Investor Relations Contact Phone: [phone]
Web: www.favrille.com; live webcast
Date of Presentation: May 5, 2005 at 4:15 p.m. local time

Company description: Favrille, Inc. (www.favrille.com) is a
biopharmaceutical company focused on the research, development and
commercialization of targeted immunotherapies for the treatment of
cancer and diseases of the immune system. The Company's lead product
candidate, FavId, is based upon unique genetic information extracted
from a patient's tumor. FavId is currently under investigation in a
pivotal Phase III clinical trial for patients with follicular B-cell
NHL and Phase II clinical trials in other B-cell NHL indications. The
Company is developing additional applications based on its
immunotherapy expertise and proprietary manufacturing technology,
including a second product candidate, FAV-201, for the treatment of
T-cell lymphoma.

Company: GTC Biotherapeutics
Ticker Symbol & Exchange: GTCB (NASDAQ)
Investor Relations Contact: Thomas Newberry
Investor Relations Contact Phone: [phone]
Web: www.gtc-bio.com
Date of Presentation: May 4, 2005 at 10:50 a.m.

Company description: GTC Biotherapeutics is a leader in the
development, production, and commercialization of therapeutic proteins
through transgenic animal technology. GTC currently has five products
in its internal pipeline and a portfolio of external program
production opportunities. GTC's lead program is ATryn(R), its
recombinant form of human antithrombin. A Market Authorization
Application is under review by the European Medicines Evaluation
Agency for the use of ATryn(R) in patients with a hereditary
antithrombin deficiency. In its external programs, GTC's technology is
used to develop transgenic production of its partners' proprietary
products, including both large-volume protein therapeutics as well as
products that are difficult to produce in significant quantities from
conventional recombinant production systems.

Company: Halozyme Therapeutics, Inc.
Ticker Symbol & Exchange: HTI (AMEX)
Investor Relations Contact: Lippert/Heilshorn & Associates
Investor Relations Contact Phone: Ina McGuinness / Bruce Voss,
310-691-7100
Web: www.halozyme.com
Date of Presentation: May 4, 2005

Company description: Halozyme is a development stage
biopharmaceutical company dedicated to developing and commercializing
recombinant human enzymes for the infertility, ophthalmology, and
oncology communities. Halozyme is developing recombinant human
hyaluronidase (rHuPH20) enzyme as a medical device (Cumulase), drug
enhancement agent (Enhanze SC), and therapeutic biologic (Chemophase).
Halozyme has received CE Mark clearance for marketing of Cumulase in
Europe and FDA 510(k) clearance for marketing in the US. An NDA has
been filed for Enhanze SC, which has received Priority Review status
and is partnered with Baxter Healthcare. Clinical trials for
Chemophase are scheduled for the 2nd half of 2005.

Company: Hana Biosciences, Inc.
Ticker Symbol & Exchange: HNAB.OB
Investor Relations Contact: Russell Skibsted
Investor Relations Contact Phone: Chief Financial Officer,
650-588-6464
Web: www.hanabiosciences.com
Date of Presentation: Thursday, May 5, at 9:05 a.m.

Company description: Hana Biosciences (OTC:HNAB) acquires,
develops, and commercializes innovative products to advance cancer
care. By collaborating with academia and research institutions, Hana
identifies development stage product candidates that address unmet
oncological needs. Hana's proven and accomplished biopharmaceutical
management team moves these unique product candidates through
translational research for timely transfer from the lab to clinical
development. Multiple technologies with well-validated mechanisms of
action and strong intellectual property rights, set the platform for
accelerated growth and speeds commercialization.

Company: The Immune Response Corporation
Ticker Symbol & Exchange: IMNR (NASDAQ)
Investor Relations Contact: Michael Green
Investor Relations Contact Phone: [phone]
Web: www.imnr.com
Date of Presentation: Wednesday, May 4, 4:15 p.m.

Company description: A biopharmaceutical company dedicated to
becoming a leading immune-based therapy company in HIV and multiple
sclerosis (MS). The Company's HIV products are based on its patented
whole-killed virus technology to stimulate HIV immune responses.
REMUNE(R), currently in Phase II trials, is being developed as a
first-line treatment for people with early-stage HIV. We have
initiated development of a new immune-based therapy, IR103, which is
currently in Phase I/II trials in Canada and the United Kingdom.

Immune Response is also developing an immune-based therapy for MS,
NeuroVax(TM), which is currently in Phase II trials and has shown
potential therapeutic value..

Company: Life Medical Sciences, Inc.
Ticker Symbol & Exchange: CHAI (OTCBB)
Investor Relations Contact: Robert P. Hickey
Investor Relations Contact Phone: [phone]
Web: www.lifemedicalsciences.com
Date of Presentation: May 5, 2005 at 8:20 -- Salon Napoleon

Company description: LMS's product development efforts are
principally focused on its lead product, REPEL-CV, a bioresorbable
adhesion barrier intended for use in cardiac surgery. In October 2003,
LMS initiated the multi-center pivotal clinical trial on REPEL-CV. In
January 2005, LMS announced that a planned interim analysis of patient
data from the REPEL-CV trial was completed by a Data and Safety
Monitoring Board ("DSMB") comprised of medical and biostatistical
specialists who are not participating in the trial. Based on data from
over forty patients, the DSMB recommended that the trial proceed as
planned and that no modifications to the trial protocol were
indicated. It is anticipated that the pivotal clinical trial will be
completed in mid 2006.

Company: Marshall Edwards, Inc
Ticker Symbol & Exchange: MSHL
Investor Relations Contact: John O'Connor
Investor Relations Contact Phone: [phone]
Web: www.marshalledwardsinc.com
Date of Presentation: May 4 at 11.55 a.m.

Company description: Marshall Edwards, Inc. is an oncology
therapeutic focussed company, which is 87% owned by Australian
flavanoid-based drug development company, Novogen Ltd. MSHL has
licensed from Novogen Limited the rights to bring phenoxodiol to
global markets. Phenoxodiol is a multiple signal transduction
regulator developed by Novogen and has reached the end of Phase II
trials. It has been awarded fast track status by the FDA for hormone
resistant prostate cancer and chemoresistant ovarian cancer. MSHL has
an option to license any of Novogen's pipeline compounds for oncology
once they reach clinical development phase with a first and last right
of refusal.

Company: MaxCyte, Inc.
Investor Relations Contact: Ronald Holtz, CFO
Investor Relations Contact Phone: [phone]
Web: www.maxcyte.com
Date of Presentation: Thursday, May 3, 2005; 8:40 a.m.

Company description: MaxCyte uses its proprietary non-viral
cell-loading technology to advance company sponsored therapeutic
programs and enable other developers of ex vivo cell therapies and
manufacturers of biotherapeutics. Maxcyte has a Phase I/II trial in
CLL and numerous partnerships with leading cell therapy companies.
MaxCyte's key value is its ability to accelerate development timelines
and reduce risk in bringing cell and gene therapies from bench to a
clinical reality. MaxCyte's technology provides an efficient and
validated clinical solution for loading various types of biomolecules
into a wide range of human primary cells and production cell lines.
For additional information contact MaxCyte at 301-944-1700 or
www.maxcyte.com.

Company: MEDICURE
Ticker Symbol & Exchange: MCU (AMEX) & MPH (TSX)
Investor Relations Contact: Hogan Mullally
Investor Relations Contact Phone: [phone]
Web: www.medicure.com
Date of Presentation: May 4

Company description: Medicure Inc. is a cardiovascular drug
discovery and development Company focused on developing effective
therapeutics for unmet needs in the field of cardiovascular medicine,
the largest pharmaceutical market sector. The Company's solid position
in this field is supported by the following attributes:

-- Cardiovascular focused pipeline: a global market of over US $70
   billion

-- Two drugs - MC-1 & MC-4232 - in advanced Phase II trials

-- Two positive Phase II trials completed

-- Unique products addressing major markets not adequately served by
   existing drugs

-- Dual action antithrombotic, MC-45308, in preclinical testing

Medicure also has a medicinal chemistry based Drug Discovery
program focused on discovery and advancement of novel small molecule,
anti-ischemics and anti-thrombotics towards human clinical studies.

Company: Meditech Research Limited
Ticker Symbol & Exchange: MTR
Investor Relations Contact: Dr. Ian Nisbet
Investor Relations Contact Phone: [phone]
Web: www.mrl.com.au
Date of Presentation: 5th May 2005

Company description: Meditech is an Australian development-stage
biotechnology company focused on developing and commercializing drugs
that improve the health and quality of life of patients with cancer
and other chronic diseases. The company has internationally-recognized
expertise in carbohydrate-based therapies, particularly products based
upon the glycosaminoglycan, hyaluronic acid (HA). Meditech scientists
have generated pre-clinical and clinical data on the use of HA as a
drug delivery platform, based upon which the company has created an
extensive portfolio of intellectual property. Meditech's Hyaluronic
Acid Chemotransport Technology (HyACT(TM)) is designed to reduce the
toxicity and quality of life problems associated with chemotherapeutic
agents.

Company: Neoprobe Corporation
Ticker Symbol & Exchange: NEOP.OB
Investor Relations Contact: The Trout Group
Investor Relations Contact Phone: Tim Ryan, 212-477-9007
Web: www.neoprobe.com
Date of Presentation: May 5, 2005, 1:00 p.m.

Company description: Neoprobe is a leader in an intraoperative
cancer staging technology known as lymphatic mapping that is the
standard of care for the staging of melanoma and breast cancers at
many cancer hospitals. Neoprobe is preparing to commence multi-center
clinical studies for a lymphatic tissue tracing agent, Lymphoseek, to
support a new drug application (NDA) for the product by mid year '06.
Neoprobe has received FDA comments to a Phase III protocol for the
evaluation of RIGScan(R) CR in primary colorectal cancer patients. In
confirming the prognostic/therapeutic endpoints, FDA has invited
Neoprobe to seek a special protocol assessment (SPA) review of the
RIGScan clinical plan. Neoprobe has formed CIRA Biosciences to explore
the development of patient specific immune therapy products that have
shown positive clinical responses in a variety of diseases.

Company: NexMed, Inc.
Ticker Symbol & Exchange: NEXM
Investor Relations Contact: Deborah Carty
Investor Relations Contact Phone: [phone] x159
Web: www.nexmed.com
Date of Presentation: May 5, 2005, 10:10 a.m., Salon Imperial

Company description: NexMed is an emerging drug developer that is
leveraging its proprietary drug delivery technology to develop a
significant pipeline of innovative pharmaceutical products to address
large unmet medical needs. The Company is also working with various
pharmaceutical companies to explore the incorporation of NexACT(R)
into their existing drugs as a means of developing new
patient-friendly transdermal products and extending patent life-spans
and brand equity.

Company: Northfield Laboratories Inc.
Ticker Symbol & Exchange: NFLD (NASDAQ)
Investor Relations Contact: Sophia H. Twaddell
Investor Relations Contact Phone: [phone]
Web: www.northfieldlabs.com
Date of Presentation: Wednesday, May 4, at 9:05 a.m. Paris

Company description: Northfield Laboratories Inc. is a leader in
developing an oxygen-carrying resuscitative fluid, PolyHeme(R), for
the treatment of urgent, large volume blood loss in trauma and
resultant surgical settings. PolyHeme(R) is a solution of chemically
modified human hemoglobin that requires no cross matching and is
therefore compatible with all blood types. It has a shelf life of over
12 months. Enrollment is currently underway in a pivotal Phase III
study of PolyHeme(R) beginning in the pre-hospital setting.

Company: Novogen Limited
Ticker Symbol & Exchange: NVGN (NASDAQ)
Investor Relations Contact: John O'Connor
Investor Relations Contact Phone: [phone]
Web: www.novogen.com
Date of Presentation: May 5 at 10.50 a.m.

Company description: Novogen Limited is an Australian
biopharmaceutical company that is specializing in the development of
therapeutics based on the isoflavonoid ring structure. Novogen, based
in Sydney, Australia, is developing a range of therapeutics across the
fields of oncology, cardiovascular disease and inflammatory diseases.
The oncology drug phenoxodiol, a multiple signal transduction
regulator has been developed by Novogen and licensed to its 87%
subsidiary, Marshall Edwards, Inc. The drug has reached the end of
Phase II trials and has been awarded fast track status by the FDA for
hormone resistant prostate cancer and chemoresistant ovarian cancer.
Other lead compounds are in development for treatment of
atherosclerosis and restenosis, and management of inflammatory bowel
disease. A wound healing formulation is also in development.

Company: OXIS International
Ticker Symbol & Exchange: OXIS (OTCBB)
Investor Relations Contact: Will Anderson
Investor Relations Contact Phone: [phone]
Web: www.oxis.com
Date of Presentation: May 4th, 2005 at 3:10

Company description: OXIS International focuses on developing
technologies and products to research, diagnose, treat and prevent
diseases associated with oxidative stress. With 45 U.S. and
international patents, OXIS offers a broad portfolio of products
worldwide. OXIS is a leading provider of commercialized
oxidative-stress assays, including its myeloperoxidase assay used to
predict early risks of cardiovascular diseases. The company is a
leading producer of the powerful antioxidant Ergothioneine, currently
used in the cosmetic industry and soon to be introduced as a
neutraceutical product. The company also holds the rights to three
therapeutic classes of compounds in the area of oxidative stress.

Company: Pro-Pharmaceuticals, Inc.
Ticker Symbol & Exchange: PRW (AMEX)
Investor Relations Contact: Tony Squeglia
Investor Relations Contact Phone: [phone]
Web: [e-mail]
Date of Presentation: May 4, 2005

Company description: Pro-Pharmaceuticals, Inc. is a development
stage biopharmaceutical company developing carbohydrate-based
compounds that enable the targeted delivery of widely used
chemotherapy drugs to cancer cells to increase efficacy and reduce
toxicity. The Company employs proprietary, non-toxic carbohydrate
compounds recognized to adhere to specific binding sites, known as
lectins, on the surface of cancer cells, to reformulate and
"Glyco-Upgrade(TM)" chemotherapies. The galactose residue side chain
attached to the carbohydrate polymer backbone targets a lectin
receptor (Galectin 3) that is specific and over-expressed on cancer
cells.

Company: Solbec Pharmaceuticals Ltd
Ticker Symbol & Exchange: SBP (ASX)
Investor Relations Contact: Stephen Carter
Investor Relations Contact Phone: + 61 (0)8 9446 7555
Web: www.solbec.com.au

Company description: Solbec Pharmaceuticals Ltd develops new
medicines that offer better treatment than those currently available
for life threatening and debilitating diseases. Solbec's current lead
compound, Coramsine(TM), has successfully completed Phase I/IIA
clinical trials in two distinct therapeutic areas, cancer and
psoriasis.

Coramsine(TM) has been shown to be an effective single agent
against cancer and to synergise with current treatments. It binds
preferentially to cancer cells and is taken up. Cellular processes
free the alkaloid from the carbohydrate parts of Coramsine(TM) which
cause necrotic cell death.

Company: Synthetic Blood International, Inc.
Ticker Symbol & Exchange: SYBD (OTCBB)
Investor Relations Contact: Jody Cain or Brandi Floberg
Investor Relations Contact Phone: [phone]
Web: www.sybd.com
Date of Presentation: May 4, 2005

Company description: Synthetic Blood develops innovative
pharmaceuticals and medical devices with oxygen therapeutic and
continuous substrate monitoring technologies with products based on
perfluorocarbon (PFC) and biosensor technologies. Its lead product,
Oyxcyte(TM), is an oxygen-carrying intravenous emulsion, intended as
an alternative to transfused blood for use in surgical and other
medical situations. Applications include stroke, myocardial infarction
and certain malignant diseases. Synthetic Blood is currently
conducting a Phase II study to evaluate Oxycyte's ability to prevent
tissue hypoxia in orthopedic surgical patients. Other pipeline
products include Fluorovent(TM), a liquid ventilator providing oxygen
exchange fluid for facilitating the treatment of lung conditions, and
a biosensor implant product for measuring glucose levels in blood the
stream.

Company: TRANSGENE
Ticker Symbol & Exchange: FR0005175080 Paris
Investor Relations Contact: Philippe Poncet
Investor Relations Contact Phone: [phone]
Web: www.transgene.fr
Date of Presentation: May 4, 2005

Company description: Transgene is a biopharmaceutical company
dedicated to the discovery and development of therapeutic vaccines and
immunotherapy products for the treatment of cancer and infectious
diseases. Transgene's operations are located in Strasbourg, France.
Transgene has 168 employees.

Transgene has advanced a large product candidate portfolio into
mid-stage clinical trials. A new therapeutic vaccine candidate against
the hepatitis C virus has recently been added to its portfolio. By
developing expertise in applied research, clinical and production
capabilities (2800 sq. meter GMPc production facility) while
maintaining broad intellectual property of over 200 patent families,
Transgene is uniquely poised to advance cancer and infectious diseases
therapies.

Company: Tripos, Inc.
Ticker Symbol & Exchange: TRPS (NASDAQ)
Investor Relations Contact: Jim Rubin, CFO
Investor Relations Contact Phone: [phone]
Web: www.tripos.com
Date of Presentation: Wednesday, May 4, 2005 at 3:50 p.m.

Company description: Tripos combines leading-edge technology and
innovative science to deliver superior chemistry-research products and
services for the biotechnology, pharmaceutical and other life science
industries. Tripos collaborates with clients to accelerate and improve
the creation of life-enhancing products. Within Tripos' Discovery
Informatics (DI) business, the company provides software products and
consulting services to develop, manage, analyze and share critical
drug discovery information. Within Tripos' Discovery Research (DR)
business, Tripos' medicinal chemists and research scientists partner
directly with clients in their research initiatives, leveraging
state-of-the-art information technologies and research facilities.
Headquartered in St. Louis, Mo., Tripos spans the world with global
research operations and an international client base.

Company: Vical Incorporated
Ticker Symbol & Exchange: VICL (NASDAQ)
Investor Relations Contact: Alan Engbring
Investor Relations Contact Phone: [e-mail], 858-646-1127
Web: www.vical.com
Date of Presentation: 5/5/05

Company description: Vical researches and develops
biopharmaceutical products based on its patented DNA delivery
technologies for the prevention and treatment of serious or
life-threatening diseases. In addition, the company has gained access
to enhancing technologies through licensing and collaborative
agreements. Independent product development efforts are focused on
vaccines for use in high-risk populations for infectious disease
targets for which there are significant U.S. needs, vaccines for
general pediatric or adult populations for infectious disease
applications, and cancer vaccines or immunotherapies which complement
existing programs and core expertise. Vical plans to continue
leveraging its patented technologies through licensing and
collaborations.

Company: Viventia Biotech Inc.
Ticker Symbol & Exchange: VBI (TSX)
Investor Relations Contact: James Smith
Investor Relations Contact Phone: [phone] ext. 229
Web: www.viventia.com
Date of Presentation: May 5, 2005, 3:30 p.m., Salon Imperial

Company description: Viventia Biotech Inc. is a biopharmaceutical
company specializing in the discovery and development of human
monoclonal antibody therapies for the treatment of cancer. Our lead
product candidate Proxinium(TM) is in multiple Phase I clinical
studies for the treatment of head and neck cancer and bladder cancer.
Phase II clinical studies with Proxinium(TM) are expected to begin in
2005. Our platform of technologies is based upon the isolation of
human monoclonal antibodies obtained from cancer patients, and the
development of those antibodies as Armed Antibodies(TM) to deliver
cytotoxic (cancer killing) "payloads" to cancer cells. We believe
that this approach has the potential to be safer and more beneficial
than existing cancer therapies

Company: VIVUS, Inc.
Ticker Symbol & Exchange: VVUS (NASDAQ)
Investor Relations Contact: Christina Weisgerber
Investor Relations Contact Phone: [phone]
Web: www.vivus.com
Date of Presentation: Thursday, May 5, 2005, 9:25 a.m.

Company description: VIVUS, Inc. is a pioneer in the research and
development of proprietary products to restore sexual function for men
and women. VIVUS' current product pipeline includes four
investigational products in late stage clinical development. For
women, VIVUS has initiated its Phase 3 programs with ALISTA(TM) for
female sexual arousal disorder, and Evamist(TM) for the alleviation of
menopausal symptoms. Testosterone MDTS(R) for the treatment of
hypoactive sexual desire disorder has completed Phase 2 development.
The MDTS system is a patented new-generation, transdermal drug
delivery technology that delivers drugs through the skin. For men,
VIVUS is developing avanafil for erectile dysfunction, which is
currently in a Phase 2 program.